A case of social phobia and avoidant personality disorder with erectile dysfunction successfully treated with venlafaxine and add-on reboxetine.
A 25-year-old man with DSM-IV-TR Axis I social phobia and Axis II avoidant personality disorder and erectile dysfunction, presenting with depression, anxiety and insomnia, responded partially to extended release oral venlafaxine (75 mg/die for 6 weeks), but developed side effects and worsening symptoms when dose was increased to 150 mg/die; he responded to a combination of 75 mg/die venlafaxine and 4 mg/die reboxetine and improved on most of his symptoms.
Pacchiarotti
Isabella
I
Department of Psychiatry, University of Rome, La Sapienza-Sant'Andrea Hospital, 1035-1039 Via di Grottarossa, 00189 Rome, Italy. isabella.pacchiarotti@uniroma1.it
Manfredi
Giovanni
G
Kotzalidis
Giorgio D
GD
Ruberto
Amedeo
A
Tatarelli
Roberto
R
Girardi
Paolo
P
D000328:Adult; D003511:Cyclohexanols / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D007172:Erectile Dysfunction / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D008297:Male; D009025:Morpholines / Q000627:therapeutic use*; D010554:Personality Disorders / Q000150:complications* / Q000188:drug therapy* / Q000523:psychology; D010698:Phobic Disorders / Q000150:complications* / Q000175:diagnosis / Q000523:psychology; D000077593:Reboxetine; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D000069470:Venlafaxine Hydrochloride
D003511:Cyclohexanols; D009025:Morpholines; D000077593:Reboxetine; D017367:Selective Serotonin Reuptake Inhibitors; D000069470:Venlafaxine Hydrochloride